Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Finasteride Market

ID: MRFR/CnM/29158-HCR
111 Pages
Chitranshi Jaiswal
Last Updated: April 06, 2026

Finasteride Market Research Report By Dosage (1 mg, 5 mg, 10 mg), By Active Ingredient (Finasteride, Dutasteride), By Application (Male Pattern Hair Loss, Benign Prostatic Hyperplasia), By Route of Administration (Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Finasteride Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Dosage (USD Billion)
  49.     4.1.1 1 mg
  50.     4.1.2 5 mg
  51.     4.1.3 10 mg
  52.   4.2 Chemicals and Materials, BY Active Ingredient (USD Billion)
  53.     4.2.1 Finasteride
  54.     4.2.2 Dutasteride
  55.   4.3 Chemicals and Materials, BY Application (USD Billion)
  56.     4.3.1 Male Pattern Hair Loss
  57.     4.3.2 Benign Prostatic Hyperplasia
  58.   4.4 Chemicals and Materials, BY Route of Administration (USD Billion)
  59.     4.4.1 Oral
  60.     4.4.2 Topical
  61.   4.5 Chemicals and Materials, BY Region (USD Billion)
  62.     4.5.1 North America
  63.       4.5.1.1 US
  64.       4.5.1.2 Canada
  65.     4.5.2 Europe
  66.       4.5.2.1 Germany
  67.       4.5.2.2 UK
  68.       4.5.2.3 France
  69.       4.5.2.4 Russia
  70.       4.5.2.5 Italy
  71.       4.5.2.6 Spain
  72.       4.5.2.7 Rest of Europe
  73.     4.5.3 APAC
  74.       4.5.3.1 China
  75.       4.5.3.2 India
  76.       4.5.3.3 Japan
  77.       4.5.3.4 South Korea
  78.       4.5.3.5 Malaysia
  79.       4.5.3.6 Thailand
  80.       4.5.3.7 Indonesia
  81.       4.5.3.8 Rest of APAC
  82.     4.5.4 South America
  83.       4.5.4.1 Brazil
  84.       4.5.4.2 Mexico
  85.       4.5.4.3 Argentina
  86.       4.5.4.4 Rest of South America
  87.     4.5.5 MEA
  88.       4.5.5.1 GCC Countries
  89.       4.5.5.2 South Africa
  90.       4.5.5.3 Rest of MEA
  91. 5 SECTION V: COMPETITIVE ANALYSIS
  92.   5.1 Competitive Landscape
  93.     5.1.1 Overview
  94.     5.1.2 Competitive Analysis
  95.     5.1.3 Market share Analysis
  96.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  97.     5.1.5 Competitive Benchmarking
  98.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  99.     5.1.7 Key developments and growth strategies
  100.       5.1.7.1 New Product Launch/Service Deployment
  101.       5.1.7.2 Merger & Acquisitions
  102.       5.1.7.3 Joint Ventures
  103.     5.1.8 Major Players Financial Matrix
  104.       5.1.8.1 Sales and Operating Income
  105.       5.1.8.2 Major Players R&D Expenditure. 2023
  106.   5.2 Company Profiles
  107.     5.2.1 Merck & Co. (US)
  108.       5.2.1.1 Financial Overview
  109.       5.2.1.2 Products Offered
  110.       5.2.1.3 Key Developments
  111.       5.2.1.4 SWOT Analysis
  112.       5.2.1.5 Key Strategies
  113.     5.2.2 Teva Pharmaceutical Industries Ltd. (IL)
  114.       5.2.2.1 Financial Overview
  115.       5.2.2.2 Products Offered
  116.       5.2.2.3 Key Developments
  117.       5.2.2.4 SWOT Analysis
  118.       5.2.2.5 Key Strategies
  119.     5.2.3 Mylan N.V. (NL)
  120.       5.2.3.1 Financial Overview
  121.       5.2.3.2 Products Offered
  122.       5.2.3.3 Key Developments
  123.       5.2.3.4 SWOT Analysis
  124.       5.2.3.5 Key Strategies
  125.     5.2.4 Aurobindo Pharma (IN)
  126.       5.2.4.1 Financial Overview
  127.       5.2.4.2 Products Offered
  128.       5.2.4.3 Key Developments
  129.       5.2.4.4 SWOT Analysis
  130.       5.2.4.5 Key Strategies
  131.     5.2.5 Sun Pharmaceutical Industries Ltd. (IN)
  132.       5.2.5.1 Financial Overview
  133.       5.2.5.2 Products Offered
  134.       5.2.5.3 Key Developments
  135.       5.2.5.4 SWOT Analysis
  136.       5.2.5.5 Key Strategies
  137.     5.2.6 Hikma Pharmaceuticals PLC (GB)
  138.       5.2.6.1 Financial Overview
  139.       5.2.6.2 Products Offered
  140.       5.2.6.3 Key Developments
  141.       5.2.6.4 SWOT Analysis
  142.       5.2.6.5 Key Strategies
  143.     5.2.7 Dr. Reddy's Laboratories Ltd. (IN)
  144.       5.2.7.1 Financial Overview
  145.       5.2.7.2 Products Offered
  146.       5.2.7.3 Key Developments
  147.       5.2.7.4 SWOT Analysis
  148.       5.2.7.5 Key Strategies
  149.     5.2.8 Sandoz International GmbH (CH)
  150.       5.2.8.1 Financial Overview
  151.       5.2.8.2 Products Offered
  152.       5.2.8.3 Key Developments
  153.       5.2.8.4 SWOT Analysis
  154.       5.2.8.5 Key Strategies
  155.   5.3 Appendix
  156.     5.3.1 References
  157.     5.3.2 Related Reports
  158. 6 LIST OF FIGURES
  159.   6.1 MARKET SYNOPSIS
  160.   6.2 NORTH AMERICA MARKET ANALYSIS
  161.   6.3 US MARKET ANALYSIS BY DOSAGE
  162.   6.4 US MARKET ANALYSIS BY ACTIVE INGREDIENT
  163.   6.5 US MARKET ANALYSIS BY APPLICATION
  164.   6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  165.   6.7 CANADA MARKET ANALYSIS BY DOSAGE
  166.   6.8 CANADA MARKET ANALYSIS BY ACTIVE INGREDIENT
  167.   6.9 CANADA MARKET ANALYSIS BY APPLICATION
  168.   6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  169.   6.11 EUROPE MARKET ANALYSIS
  170.   6.12 GERMANY MARKET ANALYSIS BY DOSAGE
  171.   6.13 GERMANY MARKET ANALYSIS BY ACTIVE INGREDIENT
  172.   6.14 GERMANY MARKET ANALYSIS BY APPLICATION
  173.   6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  174.   6.16 UK MARKET ANALYSIS BY DOSAGE
  175.   6.17 UK MARKET ANALYSIS BY ACTIVE INGREDIENT
  176.   6.18 UK MARKET ANALYSIS BY APPLICATION
  177.   6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  178.   6.20 FRANCE MARKET ANALYSIS BY DOSAGE
  179.   6.21 FRANCE MARKET ANALYSIS BY ACTIVE INGREDIENT
  180.   6.22 FRANCE MARKET ANALYSIS BY APPLICATION
  181.   6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  182.   6.24 RUSSIA MARKET ANALYSIS BY DOSAGE
  183.   6.25 RUSSIA MARKET ANALYSIS BY ACTIVE INGREDIENT
  184.   6.26 RUSSIA MARKET ANALYSIS BY APPLICATION
  185.   6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  186.   6.28 ITALY MARKET ANALYSIS BY DOSAGE
  187.   6.29 ITALY MARKET ANALYSIS BY ACTIVE INGREDIENT
  188.   6.30 ITALY MARKET ANALYSIS BY APPLICATION
  189.   6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  190.   6.32 SPAIN MARKET ANALYSIS BY DOSAGE
  191.   6.33 SPAIN MARKET ANALYSIS BY ACTIVE INGREDIENT
  192.   6.34 SPAIN MARKET ANALYSIS BY APPLICATION
  193.   6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  194.   6.36 REST OF EUROPE MARKET ANALYSIS BY DOSAGE
  195.   6.37 REST OF EUROPE MARKET ANALYSIS BY ACTIVE INGREDIENT
  196.   6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  197.   6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  198.   6.40 APAC MARKET ANALYSIS
  199.   6.41 CHINA MARKET ANALYSIS BY DOSAGE
  200.   6.42 CHINA MARKET ANALYSIS BY ACTIVE INGREDIENT
  201.   6.43 CHINA MARKET ANALYSIS BY APPLICATION
  202.   6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  203.   6.45 INDIA MARKET ANALYSIS BY DOSAGE
  204.   6.46 INDIA MARKET ANALYSIS BY ACTIVE INGREDIENT
  205.   6.47 INDIA MARKET ANALYSIS BY APPLICATION
  206.   6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  207.   6.49 JAPAN MARKET ANALYSIS BY DOSAGE
  208.   6.50 JAPAN MARKET ANALYSIS BY ACTIVE INGREDIENT
  209.   6.51 JAPAN MARKET ANALYSIS BY APPLICATION
  210.   6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  211.   6.53 SOUTH KOREA MARKET ANALYSIS BY DOSAGE
  212.   6.54 SOUTH KOREA MARKET ANALYSIS BY ACTIVE INGREDIENT
  213.   6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  214.   6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  215.   6.57 MALAYSIA MARKET ANALYSIS BY DOSAGE
  216.   6.58 MALAYSIA MARKET ANALYSIS BY ACTIVE INGREDIENT
  217.   6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION
  218.   6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  219.   6.61 THAILAND MARKET ANALYSIS BY DOSAGE
  220.   6.62 THAILAND MARKET ANALYSIS BY ACTIVE INGREDIENT
  221.   6.63 THAILAND MARKET ANALYSIS BY APPLICATION
  222.   6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  223.   6.65 INDONESIA MARKET ANALYSIS BY DOSAGE
  224.   6.66 INDONESIA MARKET ANALYSIS BY ACTIVE INGREDIENT
  225.   6.67 INDONESIA MARKET ANALYSIS BY APPLICATION
  226.   6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  227.   6.69 REST OF APAC MARKET ANALYSIS BY DOSAGE
  228.   6.70 REST OF APAC MARKET ANALYSIS BY ACTIVE INGREDIENT
  229.   6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION
  230.   6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  231.   6.73 SOUTH AMERICA MARKET ANALYSIS
  232.   6.74 BRAZIL MARKET ANALYSIS BY DOSAGE
  233.   6.75 BRAZIL MARKET ANALYSIS BY ACTIVE INGREDIENT
  234.   6.76 BRAZIL MARKET ANALYSIS BY APPLICATION
  235.   6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  236.   6.78 MEXICO MARKET ANALYSIS BY DOSAGE
  237.   6.79 MEXICO MARKET ANALYSIS BY ACTIVE INGREDIENT
  238.   6.80 MEXICO MARKET ANALYSIS BY APPLICATION
  239.   6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  240.   6.82 ARGENTINA MARKET ANALYSIS BY DOSAGE
  241.   6.83 ARGENTINA MARKET ANALYSIS BY ACTIVE INGREDIENT
  242.   6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION
  243.   6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  244.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE
  245.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ACTIVE INGREDIENT
  246.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  247.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  248.   6.90 MEA MARKET ANALYSIS
  249.   6.91 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE
  250.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ACTIVE INGREDIENT
  251.   6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  252.   6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  253.   6.95 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE
  254.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ACTIVE INGREDIENT
  255.   6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  256.   6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  257.   6.99 REST OF MEA MARKET ANALYSIS BY DOSAGE
  258.   6.100 REST OF MEA MARKET ANALYSIS BY ACTIVE INGREDIENT
  259.   6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION
  260.   6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  261.   6.103 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  262.   6.104 RESEARCH PROCESS OF MRFR
  263.   6.105 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  264.   6.106 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  265.   6.107 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  266.   6.108 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  267.   6.109 CHEMICALS AND MATERIALS, BY DOSAGE, 2024 (% SHARE)
  268.   6.110 CHEMICALS AND MATERIALS, BY DOSAGE, 2024 TO 2035 (USD Billion)
  269.   6.111 CHEMICALS AND MATERIALS, BY ACTIVE INGREDIENT, 2024 (% SHARE)
  270.   6.112 CHEMICALS AND MATERIALS, BY ACTIVE INGREDIENT, 2024 TO 2035 (USD Billion)
  271.   6.113 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
  272.   6.114 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Billion)
  273.   6.115 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  274.   6.116 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  275.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  276. 7 LIST OF TABLES
  277.   7.1 LIST OF ASSUMPTIONS
  278.     7.1.1
  279.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  280.     7.2.1 BY DOSAGE, 2025-2035 (USD Billion)
  281.     7.2.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  282.     7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
  283.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  284.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  285.     7.3.1 BY DOSAGE, 2025-2035 (USD Billion)
  286.     7.3.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  287.     7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
  288.     7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  289.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  290.     7.4.1 BY DOSAGE, 2025-2035 (USD Billion)
  291.     7.4.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  292.     7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
  293.     7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  294.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  295.     7.5.1 BY DOSAGE, 2025-2035 (USD Billion)
  296.     7.5.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  297.     7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
  298.     7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  299.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  300.     7.6.1 BY DOSAGE, 2025-2035 (USD Billion)
  301.     7.6.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  302.     7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
  303.     7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  304.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  305.     7.7.1 BY DOSAGE, 2025-2035 (USD Billion)
  306.     7.7.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  307.     7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
  308.     7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  309.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  310.     7.8.1 BY DOSAGE, 2025-2035 (USD Billion)
  311.     7.8.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  312.     7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
  313.     7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  314.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  315.     7.9.1 BY DOSAGE, 2025-2035 (USD Billion)
  316.     7.9.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  317.     7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
  318.     7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  319.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  320.     7.10.1 BY DOSAGE, 2025-2035 (USD Billion)
  321.     7.10.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  322.     7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
  323.     7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  324.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  325.     7.11.1 BY DOSAGE, 2025-2035 (USD Billion)
  326.     7.11.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  327.     7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
  328.     7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  329.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  330.     7.12.1 BY DOSAGE, 2025-2035 (USD Billion)
  331.     7.12.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  332.     7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
  333.     7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  334.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  335.     7.13.1 BY DOSAGE, 2025-2035 (USD Billion)
  336.     7.13.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  337.     7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
  338.     7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  339.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  340.     7.14.1 BY DOSAGE, 2025-2035 (USD Billion)
  341.     7.14.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  342.     7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
  343.     7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  344.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  345.     7.15.1 BY DOSAGE, 2025-2035 (USD Billion)
  346.     7.15.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  347.     7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
  348.     7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  349.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  350.     7.16.1 BY DOSAGE, 2025-2035 (USD Billion)
  351.     7.16.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  352.     7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
  353.     7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  354.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  355.     7.17.1 BY DOSAGE, 2025-2035 (USD Billion)
  356.     7.17.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  357.     7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
  358.     7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  359.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  360.     7.18.1 BY DOSAGE, 2025-2035 (USD Billion)
  361.     7.18.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  362.     7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
  363.     7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  364.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  365.     7.19.1 BY DOSAGE, 2025-2035 (USD Billion)
  366.     7.19.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  367.     7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
  368.     7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  369.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  370.     7.20.1 BY DOSAGE, 2025-2035 (USD Billion)
  371.     7.20.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  372.     7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
  373.     7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  374.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  375.     7.21.1 BY DOSAGE, 2025-2035 (USD Billion)
  376.     7.21.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  377.     7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
  378.     7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  379.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  380.     7.22.1 BY DOSAGE, 2025-2035 (USD Billion)
  381.     7.22.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  382.     7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
  383.     7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  384.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  385.     7.23.1 BY DOSAGE, 2025-2035 (USD Billion)
  386.     7.23.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  387.     7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
  388.     7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  389.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  390.     7.24.1 BY DOSAGE, 2025-2035 (USD Billion)
  391.     7.24.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  392.     7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
  393.     7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  394.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  395.     7.25.1 BY DOSAGE, 2025-2035 (USD Billion)
  396.     7.25.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  397.     7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
  398.     7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  399.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  400.     7.26.1 BY DOSAGE, 2025-2035 (USD Billion)
  401.     7.26.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  402.     7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
  403.     7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  404.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  405.     7.27.1 BY DOSAGE, 2025-2035 (USD Billion)
  406.     7.27.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  407.     7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
  408.     7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  409.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  410.     7.28.1 BY DOSAGE, 2025-2035 (USD Billion)
  411.     7.28.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  412.     7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
  413.     7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  414.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  415.     7.29.1 BY DOSAGE, 2025-2035 (USD Billion)
  416.     7.29.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  417.     7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
  418.     7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  419.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  420.     7.30.1 BY DOSAGE, 2025-2035 (USD Billion)
  421.     7.30.2 BY ACTIVE INGREDIENT, 2025-2035 (USD Billion)
  422.     7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
  423.     7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  424.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  425.     7.31.1
  426.   7.32 ACQUISITION/PARTNERSHIP
  427.     7.32.1

Chemicals and Materials Market Segmentation

Chemicals and Materials By Dosage (USD Billion, 2025-2035)

  • 1 mg
  • 5 mg
  • 10 mg

Chemicals and Materials By Active Ingredient (USD Billion, 2025-2035)

  • Finasteride
  • Dutasteride

Chemicals and Materials By Application (USD Billion, 2025-2035)

  • Male Pattern Hair Loss
  • Benign Prostatic Hyperplasia

Chemicals and Materials By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Topical

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $ $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions